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in the range of 40%.1 Such cancer detection 
rate (cDr) drops to approximately 25% in 
the setting of screening programs, i.e. patients 
with serum PSa between 2.5 and 10 ng/ml.2
Predictive models that combine PSa and 
Dre with age and prostate volume, other two 
readily available clinical parameters that cor-
relate with the risk of being diagnosed with 
Prostate biopsy (PBx) is the standard meth-od for diagnosing prostate cancer (Pca) 
however the diagnostic yield of this procedure 
remains low. as a matter of fact, in current 
clinical practice the diagnostic yield of a first 
extended PBx prompted by an elevated serum 
prostate-specific antigen (PSA) level and/or an 
abnormal digital rectal examination (Dre) is 
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a B S T r a c T
BacKgroUnD: The assessment of lower urinary tract symptoms (lUTS) is common part of urological investigation. 
furthermore, patients bother of prostate cancer (Pca) when they are affected of lUTS. This study was aimed to deter-
mine whether the presence and severity of lUTS, as assessed by the international Prostate Symptoms Score (iPSS), could 
help to identify patients at higher risk of prostate cancer (Pca) on prostate biopsy (PBx). in this effort, an initial Pca pre-
dictive model was calculated and iPSS was subsequently added. The diagnostic accuracy of both models was compared.
MeTHoDS: The analysis of prospectively collected data of patients scheduled for PBx at four academic hospitals be-
tween January 2012 and June 2015 was performed. Univariate and multivariate analysis assessed the correlation between 
the iPSS and the risk of being diagnosed with Pca; receiver operator characteristic curve (roc) analysis evaluated the 
predictive models including or not the iPSS.
RESULTS: Of the 1366 enrolled patients, 706 (52%) were diagnosed with PCa. Patients with PCa had a significantly 
lower iPSS (10.6±7.4 vs. 12.7±8.1) than those with benign diagnosis. Multivariate logistic regression analysis showed 
that age, prostate-specific antigen (PSA), prostate volume and IPSS were the most significant predictors of PBx outcome, 
(or 1.61, P=0.001; or 1.20, P=0.001; or 0.97, P=0.001; or 0.74, P=0.004; respectively). roc curve analysis showed 
that the addition of IPSS to the predictive model based on age, PSA, DRE and prostate volume significantly improved the 
model diagnostic accuracy (aUc: 0.776 vs. 0.652; P=0.001).
conclUSionS: Presence and severity of lUTS are inversely correlated with the risk of being diagnosed with Pca at 
PBx. incorporating the iPSS into predictive models may reduce the risk of unnecessary PBxs.
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lower urinary tract symptoms are inversely correlated with the risk of prostate cancer on prostate biopsy. Minerva Urol nefrol 
2017;69:486-92. Doi: 10.23736/S0393-2249.17.02737-0)
Key words: lower urinary tract symptoms - Biopsy - Prostatic neoplasms.
Minerva Urologica e nefrologica 2017 october;69(5):486-92
Doi: 10.23736/S0393-2249.17.02737-0
© 2017 eDiZioni Minerva MeDica
online version at http://www.minervamedica.it
                  COPYRIGHT© 2017 EDIZIONI MINERVA MEDICA 
Th
is
 d
oc
um
en
t i
s 
pr
ot
ec
te
d 
by
 in
te
rn
a
tio
na
l c
op
yr
ig
ht
 la
w
s.
N
o 
ad
di
tio
na
l r
ep
ro
du
ct
io
n 
is 
au
th
or
ize
d.
It 
is
 p
er
m
itt
ed
 fo
r 
pe
rs
on
al
 u
se
 to
 d
ow
n
lo
ad
 a
nd
 s
av
e
 o
n
ly 
on
e 
file
 a
nd
 p
rin
t o
nl
y 
on
e 
co
py
 o
f t
hi
s 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 m
ak
e
 a
dd
itio
na
l c
op
ie
s
(ei
the
r s
po
rad
ica
lly
 o
r s
ys
te
m
at
ica
lly
,
 
e
ith
er
 p
rin
te
d 
or
 e
le
ct
ro
ni
c) 
of 
the
 A
rtic
le
 fo
r 
a
ny
 p
ur
po
se
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 d
ist
rib
u
te
 th
e 
el
ec
tro
ni
c 
co
py
 o
f t
he
 a
rti
cl
e 
th
ro
ug
h 
on
lin
e 
in
te
rn
e
t a
nd
/o
r i
nt
ra
n
e
t f
ile
 s
ha
rin
g 
sy
st
em
s,
 
e
le
ct
ro
ni
c 
m
ai
lin
g 
or
 a
ny
 o
th
er
m
e
a
n
s 
w
hi
ch
 m
ay
 a
llo
w
 a
cc
e
ss
 to
 th
e 
Ar
tic
le
.
Th
e 
us
e 
of
 a
ll 
or
 a
ny
 p
ar
t o
f t
he
 A
rti
cl
e 
fo
r 
a
ny
 C
om
m
er
cia
l U
se
 is
 n
ot
 p
er
m
itt
ed
.T
he
 c
re
at
io
n 
of
 d
er
iva
tiv
e
 w
o
rk
s 
fro
m
 th
e 
Ar
tic
le
 is
 n
ot
 p
er
m
itt
ed
.T
he
 p
ro
du
ct
io
n 
of
 re
pr
in
ts
 fo
r 
pe
rs
on
al
 o
r c
om
m
er
cia
l u
se
 is
n
o
t p
er
m
itt
ed
.I
t i
s 
no
t p
er
m
itt
ed
 to
 re
m
ov
e,
 
co
ve
r,
 
ov
e
rla
y, 
o
bs
cu
re
,
 
bl
oc
k,
 o
r c
ha
ng
e 
an
y 
co
py
rig
ht
 n
ot
ice
s 
or
 te
rm
s 
o
f u
se
 w
hi
ch
 th
e 
Pu
bl
is
he
r m
ay
 p
os
t o
n 
th
e 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 fr
a
m
e
 o
r 
u
se
 fr
a
m
in
g 
te
ch
ni
qu
es
 to
 e
nc
lo
se
 a
ny
 tr
a
de
m
ar
k,
 lo
go
,
o
r 
o
th
er
 p
ro
pr
ie
ta
ry
 in
fo
rm
a
tio
n 
of
 th
e 
Pu
bl
is
he
r.
UrinarY SYMPToMS anD ProSTaTe cancer cicione
vol. 69 - no. 5 Minerva Urologica e nefrologica 487
and severity of lUTS, assessed by the interna-
tional Prostate Symptom Score (iPSS), predict 
the risk of being diagnosed with Pca on PBx; 
2) the addition of the iPSS improves the diag-
nostic accuracy of the predictive model based 
on age, PSa, Dre and prostate volume.
Materials and methods
Data of patients scheduled for ultrasound-
guided transrectal PBx at four urological ter-
tiary academic hospitals because of increased 
serum PSA (≥4 ng/mL) and/or abnormal DRE 
were prospectively entered into the institutional 
review board approved database of each institu-
tion. All patients filled in the IPSS questionnaire 
and underwent PSa measurement before tran-
srectal ultrasonography (TrUS), which was used 
to determine prostate volume by means of the 
ellipse formula and to guide transrectal prostate 
sampling. following periprostatic nerve block or 
topical anesthetic creams,12 all patients received 
an extended PBx including 12 to 18 cores.
Pca, have been shown to provide better pre-
dictive accuracy than PSa and Dre.3 There-
fore, the identification of further non-invasive 
and readily available clinical predictors that 
would increase the predictive accuracy of such 
models would be extremely welcome.
in clinical practice, candidates to PBx have 
been seeking urological consultation because 
of an elevated serum PSa or, more often, be-
cause of lower urinary tract symptoms (lUTS) 
leading to the clinical findings of an elevated 
serum PSa and/or an abnormal Dre. This ob-
servation has opened a debate regarding the 
correlation between lUTS and the risk of be-
ing diagnosed with Pca. To date, some studies 
have shown a positive while others a negative 
correlation between the two conditions (Table 
i);4-11 such discrepancy is probably due to the 
fact that most studies suffer biases such as het-
erogeneous patients’ population, lack of vali-
dated questionnaires, and retrospective nature.
The present multicenter study therefore 
aimed to determine whether: 1) the presence 
Table I.—The main studies on prostate cancer and urinary symptoms correlation, an overview.
author and publication year Study setting Sample size patients Mean finding and study features
catalona et al. 1994 4 Pca screening study 6630 absence of lUTS is predictive of Pca
Porter et al. 2004 5 Prospective study 411 aUaSS less than 7 is predictive of a 
positive biopsy - a sextant biopsy 
sampling was also used
collin et al. 2008 6 Pca treatments comparison 
PROTECT Study
65871 LUTS among men with a PSA level of ≥3 
ng/ml were negatively associated with 
prostate cancer
random cohort sapling, icS male 
questionnaire
frånlund et al. 2012 7 Pca screening study 
Gothenburg study
2353 Presence of voiding symptoms were all 
inversely associated with the risk of 
detecting prostate cancer in a screening 
setting. a self-administrated questionnaire 
was used
ito et al. 2013 8 retrospective biopsy 
cohort analysis
1467 absent or mild lower urinary tract 
symptoms are positively associated with 
prostate cancer and high-grade disease 
regardless of the prostate volume
oh et al. 2013 9 retrospective biopsy 
cohort analyses
3107 Pca was detected less commonly among 
men with higher lUTS scored by iPSS
Matsubara et al., 2006 10 Pca screening 3511
178 underwent biopsy
No significant difference was noted in the 
iPSS scores between men with cancer and 
the others sextant sampling
Martin et al. 2008 11 Prospective 
screening study
21159 lUTS are positively associated with 
localized prostate cancer. no data on 
biopsy sampling
Pca: prostate cancer; lUTS: lower urinary tract symptoms; aUaSS: american Urological association Symptom Score; iPSS: international 
Prostate Symptom Score.
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Results
Between January 2012 and June 2015, a to-
tal of 1736 patients underwent TrUS-guided 
PBx at the four institutions; 1366 patients met 
the inclusion criteria and were enrolled in the 
present study (figure 1). Their descriptive 
characteristics are summarized in Table ii. 
Pca was found in 706 (52%) patients, while 
the remaining 660 (48%) had no evidence of 
malignancy.
Univariate analysis showed a statistically 
significant difference in all tested variables 
(age, PSa, Dre, prostate volume and iPSS) 
between patients with and without Pca (Table 
ii). Multivariate logistic regression analysis 
showed that age, PSa, prostate volume and 
IPSS were the most significant predictors of 
PBx outcome, with the Hosmer-lemeshow 
statistics showing adequate model calibration 
(Tables iii, iv). interestingly, the Pca detec-
tion rate was found to be inversely correlated 
to lUTS severity.
Men who had previously undergone PBx 
or invasive treatment for benign prostatic 
hyperplasia, or with dwelling urethral cath-
eters, or with a serum PSa level above 20 
ng/ml, or with high-grade prostatic intraepi-
thelial neoplasia (HgPin) or atypical small 
acinar proliferation (aSaP) of prostate 
were excluded from the present case-control 
study.
finally, all participating sites provided the 
necessary institutional data-sharing agree-
ments that included both local ethical com-
mittee approval and patient written consent to 
clinical data access for research purpose.
Statistical analysis
clinical characteristics were considered 
continuous variables and reported as means; 
those with normal distribution, according to 
the Kolmogorov-Smirnov Test, were com-
pared by Student’s t-test for paired or unpaired 
data, whereas those with a non-parametric 
distribution were compared by the Mann-
Whitney U-Test for independent groups. fre-
quencies were compared by the χ2 Test. The 
combined predictive effect of the covariates 
was tested by logistic regression analysis, per-
forming a backward selection procedure with 
a removal criterion of P>0.10 based on the 
likelihood ratio test. Model calibration was 
measured by the Hosmer-lemeshow goodness 
of fit test, with P<0.05 considered statistically 
significant.
finally, receiver operator characteristic 
(roc) curves analysis was used to determine 
whether the addition of the iPSS increased 
the predictive accuracy of multivariate logis-
tic regression models based on standard clini-
cal parameters (age, PSa, Dre, and prostate 
volume). iPSS as symptom severity index 
was categorized into mild (range score 0-7), 
moderate (range score 8-19) and severe (range 
score 20-35).13
all records were collected in a common 
dedicated datasheet and analyzed using SPSS 
v. 19 software (SPSS inc, iBM corp, Somers, 
NY, USA). Statistical significance was set at 
P<0.05.
figure 1.—algorithm showing patients selection and exclu-
sion criteria for present study.
Table II.—Patients features according to prostate bi-
opsy diagnosis.
Mean±SD or cases (%) cancern. 706
Benign
n. 660 P
age, years 69.1±7.5 65.6±7.4 0.001
Prostate volume, cc 46.5±23.1 64.2±29.2 0.001
PSa, ng/ml 7.7±3.8 6.7± 3.2 0.001
iPSS total 10.6±7.4 12.7±8.1 0.001
Positive DRE findings 142 (19.5) 40 (5.7) 0.001§
luts severity
Mild (iPSS 1-7), 509 292 (57.4) 217 (42.6) 0.001§
Moderate (iPSS 8-19), 607 315 (51.9) 292 (48.1)
Severe (iPSS 20-35), 250 99 (39.6) 151 (60.4)
Student t-test and §χ2 Test; iPSS: international Prostate Symptom 
Score; Pvr: post void residual urine volume; Dre: digital rectal 
examination.
1736 pts
undergone to prostate biopsy
1366 pts
clinical data analyzed
706 (52%)
prostate cancer
660 (48%)
benign diagnosis
370 excluded because of
- Bladder catheter
-  Diagnosis of aSaP  
or HgPin
- Bladder stone
- TUrP
-  incomplete clinical record
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lUTS and the risk of being diagnosed with 
Pca. noteworthy, the multivariate model used 
to estimate the association between symptoms 
and cancer diagnosis was adjusted for age, 
PSa and paternal or fraternal history of Pca, 
while lUTS were measured by the shortened 
11-item version of International Continence 
Society male questionnaire.14 Unfortunately, 
the authors could not include prostate volume 
and DRE findings due to the preliminary study 
design though, as they acknowledged, such 
parameters would be considered in any study 
evaluating predictive models for Pca.5
finally, roc curve analysis (figure 2) 
showed that the addition of the iPSS to the 
multivariate logistic regression model based 
on standard clinical parameters (age, PSa, 
DRE and prostate volume) significantly in-
creased the model predictive accuracy (aUc 
0.776 vs. 0.652, respectively; P=0.001).
Discussion
The present study confirmed that patients 
with Pca are older, have higher PSa levels 
and smaller prostate volume than those with-
out Pca. it also demonstrated an inverse corre-
lation between lUTS, as assessed by the iPSS, 
and the risk of candidates to PBx being diag-
nosed with Pca, therefore adding information 
to this controversial issue.
in 1994, catalona et al.4 first pointed out 
that the absence of lUTS was predictive of 
Pca in patients scheduled for PBx because of 
an elevated PSA (≥4 ng/mL) and/or suspicious 
DRE findings. This finding was confirmed in 
a subsequent prospective study whereby an 
american Urological association Symptom 
Score (aUaSS) less than 7 was predictive of 
positive PBx.5 However, both studies relied on 
a sextant prostate sampling.
in a cross-sectional analysis including 
65871 patients from the ProtecT study (Pros-
tate testing for cancer and Treatment), collin 
et al.6 demonstrated, in men with a PSa level 
of ≥3 ng/mL, an inverse correlation between 
figure 2.—receiver operating characteristic (roc) curves 
comparing predictive models of prostate cancer based on 
clinical parameters. The standard model (SM) includes age, 
prostate specific antigen, prostate volume, digital rectal ex-
amination finding. IPSS models include SM plus Interna-
tional Prostatic Symptoms Score (iPSS) analyzed both as 
categorical (iPSS severity) and ordinal (iPSS Score) vari-
able.
Table III.—Logistic model assessing clinical and 
pathological variables predictive of prostate can-
cer on prostate biopsy. IPSS analyzed as ordinal 
variable.
odds 
ratio
95% 
confidence 
interval P
lower 
limit
Upper 
limit
age, years 1.61 1.41 1.81 0.001
Prostate volume, cc 0.97 0.96 0.97 0.001
PSa, ng/ml 1.20 1.16 1.25 0.001
DRE findings 1.77 0.96 3.26 0.06
iPSS# 0.74 0.61 0.91 0.004
Hosmer-lemeshow fit Test 8 P=0.45. 
Dre: digital rectal examination; iPSS: international Prostate Symp-
tom Score.
#increasing of one unit in iPSS Score up to 35.
Table IV.—Logistic model assessing clinical and 
pathological variables predictive of prostate cancer 
on prostate biopsy. IPSS analyzed as symptom index 
gravity.
odds 
ratio
95% 
confidence 
interval P
lower 
limit
Upper 
limit
age, years 1.06 1.04 1.08 0.001
Prostate volume, cc 0.97 0.96 0.97 0.001
PSa, ng/ml 1.10 1.05 1.15 0.001
DRE findings 1.82 0.99 3.33 0.53
luts severity#
Moderate (iPSS 8-19) 0.80 0.58 0.08 0.155
Severe (iPSS 20-35) 0.56 0.37 0.84 0.006
Hosmer-lemeshow fit Test 12.8 P=0.11.
Dre: digital rectal examination; iPSS: international Prostate Symp-
tom Score.
#mild severity category vs. moderate and severe.
Se
ns
iti
vi
ty
Specificity
Model AUC 95% CI
Standard (SM) 0.652 0.619-0.685
SM+iPSS
severity 0.775 0.747-0.803
SM+iPSS score 0.776 0.749-0.804
AUC comparison P value
SM vs. iPSS severity 0.001
0.001
0.345
SM vs. iPSS severity
iPSS score vs. iPSS 
severity
SM
SM+iPSS severity
SM+iPSS score
reference line
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lUTS prompt the search for otherwise unsus-
pected cancers, thus allowing to detect more 
localized cancers in patients who would have 
not been investigated in the absence of such 
symptoms.
Taking all these findings together, it could 
be assumed that, out of the setting of PSa 
screening programs, men with lUTS are more 
likely than the asymptomatic ones to undergo 
urological investigations and, therefore, to be 
found with abnormal PSA and/or DRE find-
ings prompting PBx. in men scheduled for 
PBx because of abnormal PSa and/or Dre 
findings, however, there is an inverse correla-
tion between presence and severity of lUTS 
and the risk of being diagnosed with Pca.
The potential relationship between lUTS 
and increased serum PSa has been pointed 
out by laniado et al. already in 2004,16 as they 
demonstrated that high PSa levels in patients 
with LUTS were significantly associated with 
bladder outlet obstruction (Boo), resulting 
in 89% of patients with PSa >4 ng/ml hav-
ing Boo due to benign prostatic obstruction 
(BPo). it is attractive to assume that the in-
creased voiding pressure due to Boo/BPo 
could lead to reflux of urine into prostatic 
ducts with consequent inflammation, PSA in-
crease and consequent potentially unnecessary 
PBx. further evidence to such hypothesis has 
been provided by two recent studies cormio et 
al.17, 18 testing the correlation between objec-
tive parameters suggestive for Boo, such as 
peak flow rate and post-void residual urinary 
volume and the risk of being diagnosed with 
Pca at PBx. one study 17 showed an inverse 
correlation between the post-void residual uri-
nary volume and the risk of being diagnosed 
with Pca; the other one 18 showed an inverse 
correlation between the presence of Boo, as 
determined by a peak flow rate <10 mL/s, and 
the risk of being diagnosed with Pca. inter-
estingly, the addition of post-void residual 
urinary volume to a multivariate model based 
on standard clinical factors (age, PSa, Dre 
and prostate volume) significantly increased 
the predictive performance of the model in the 
overall population (79% vs. 77%; P=0.001) 
as well as in the subset of patients with PSa 
The gothenburg randomized Screening 
Trial,7 an observational study branch of the 
european randomized Study of Screening 
for prostate cancer (erSPc) 15 performed to 
assess the impact of PSa screening on mor-
tality, again demonstrated that, in men with a 
PSA level of ≥3 ng/mL, the absence of voiding 
symptoms was an independent risk factor for 
Pca detection. This study included age, total 
PSa, free/total PSa ratio, and prostate vol-
ume in the multivariate logistic model dem-
onstrating the inverse correlation (or 0.78, 
95% ci: 0.63-0.98, P=0.032) between void-
ing symptoms and Pca diagnosis, but voiding 
symptoms were investigated by a self-admin-
istrated questionnaire contemplating just three 
answers (1. no symptoms; 2. minor/moderate 
symptoms; 3. major/severe symptoms).
finally, two recent retrospective PBx co-
hort analyses 8, 9 confirmed the inverse corre-
lation between the iPSS and the risk of being 
diagnosed with Pca in the setting of extended 
(≥12-core) PBx. To note a multivariate logistic 
regression models including age, PSa, Dre, 
prostate volume and other clinical variables was 
used. furthermore, one of those studies 8 also 
used roc curve analysis to determine whether 
the addition of the iPSS increased the accuracy 
of the multivariate model devised for the detec-
tion of Pca. oh’s et al.9 did not show a statisti-
cally significative improvement by incorporat-
ing iPSS to the Pca predictive model. However, 
iPSS was considered as a dichotomous variable 
according to the median value (more or less 
11) and a notable difference in cancer detection 
rate occurs between oh’s study and the present 
study (30% vs. 52%, respectively).
in contrast to the above-mentioned stud-
ies, Matsubara et al.10 found no correlation 
between the iPSS and the risk of being di-
agnosed with Pca, but their study relied on 
a sextant prostate sampling. Martin et al.11 
pointed out a direct correlation between lUTS 
and Pca. However, that study was designed to 
assess the association of lUTS with a subse-
quent Pca diagnosis over a follow-up period 
of almost ten years and showed a positive as-
sociation between lUTS and localized but not 
advanced Pca. The authors hypothesized that 
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variable for its confined value or categorical 
variable when it is considered as symptoms se-
verity index.
Until the role of PSa screening will be ful-
ly elucidated, lUTS remain one of the main 
reason for men seeking urological care. The 
present multicenter prospective study dem-
onstrated that, in candidates to PBx because 
of an elevated PSa and/or a suspicious Dre, 
there is an inverse correlation between pres-
ence and severity of lUTS, as assessed by the 
iPSS, and the risk of being diagnosed with 
Pca. although rating a iPSS threshold to 
avoid prostate biopsy was unable, the present 
study supports that the assessment of clinical 
lUTS is a daily correct clinical practice to 
perform before scheduling patients to pros-
tate biopsy.
That finding was supported by increasing 
the predictive accuracy of the model based on 
standard clinical parameters (age, PSa, Dre 
and prostate volume) and iPSS, thus providing 
grounds for incorporating this simple non-in-
vasive clinical parameter into currently avail-
able predictive models.
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levels up to 10 ng/ml (74.3% vs. 71.7%; 
P=0.005). Similarly, the present study showed 
that the addition of the iPSS to the multivariate 
logistic regression model based on standard 
clinical parameters (age, PSa, Dre and pros-
tate volume) significantly increased the model 
predictive accuracy (aUc 0.776 vs. 0.652, 
respectively; P=0.001). That finding was con-
firmed by analyzing IPSS both as ordinal vari-
able (each score) and categorical (mild lUTS 
vs. moderate or severe lUTS, Table iii) due to 
the dual interpretation of iPSS.
Unfortunately, the present study did not ad-
dressed whether the addition of all three pa-
rameters (iPSS, post-void residual urinary 
volume and bladder outlet obstruction) would 
have further increased the predictive accuracy 
of the model based on standard clinical param-
eters (age, PSa, Dre and prostate volume) as 
post-void residual urinary volume and bladder 
outlet obstruction were not collected at all par-
ticipating centers. This issue deserves further 
investigations.
Limitations of the study
Study limitations include a study population 
consisting of white men only, absence of data 
about lUTS medication, lack of an external or 
centralized pathological review, lack of a stan-
dard number of cores — though all patients 
received an extended PBx including 12 to 18 
cores. Similar to other studies, this study was 
not able to assess the cause of lUTS (i.e. pros-
tatic inflammation, infection, benign prostatic 
hyperplasia or cancer) due both the absence 
of a centralized pathological analysis and data 
on objective findings (i.e. urodynamic study). 
Then, data about lUTS medication were un-
available, making a more accurate cohort analy-
sis unfeasible (i.e. stratifying patients according 
to lUTS medication or histological diagnosis)
Conclusions
The present study analyzed iPSS as both or-
dinal and categorical variable in order to avoid 
statistical bias related to the nature of iPSS 
variable. iPSS needs to be counted as ordinal 
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